1. Pink Sheet
  2. >>Market Access

Medicare Price ‘Negotiation’ Would Have Stymied Verzenio Advance In Early Cancer – Lilly’s Ricks

 
• By Cathy Kelly

‘It takes longer than nine years’ to profit from small molecule drug R&D, company CEO maintains in arguments against the negotiation process, and its timelines, in the Senate drug pricing reform legislation.

Lilly Gets Specific About The Innovation Argument Against Price Negotiation • Source: Shutterstock

Eli Lilly and Company CEO David Ricks took aim at the Medicare price “negotiation” provision in the fast-moving Senate legislation on drug pricing reform by explaining how it would upend the company’s oncology drug development efforts, which are focused on small molecule drugs like its successful Verzenio.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Pricing Debate

More from Market Access